Variables | Mean % ± SD |
---|---|
Domain A: Indications for TNF inhibitors | |
Diagnosis of SpA according to classification criteria* | 59.6 ± 3.8 |
Active disease | 77.6 ± 5.7 |
Active disease ≥ 4 wks | 31.7 ± 5.5 |
Despite optimal treatment | 78.7 ± 3.9 |
Domain B: Pretherapeutic monitoring | |
Infection | |
TB detection | 99.9 ± 0.1 |
Chest radiograph | 93.3 ± 2.7 |
Ongoing infection | 46.2 ± 6.5 |
Blood count | 95.5 ± 2.1 |
HIV serology | 79.8 ± 5.6 |
Hepatitis B and C serologies | 93.1 ± 2.3 |
Tetanus vaccine | 87.8 ± 4.3 |
Pneumococcal vaccine | 83.8 ± 4.3 |
Influenza vaccine | 60.8 ± 6.1 |
Dental status | 61.4 ± 6.7 |
Neoplasia | |
Cancer history | 62.8 ± 6.5 |
Cancer screening | 52.9 ± 6.6 |
Adenopathy | 23.9 ± 5.6 |
Cancer symptoms | 33.7 ± 6.0 |
SPEP test | 74.7 ± 5.4 |
MS | |
MS history | 49.1 ± 7.0 |
Search for demyelinating disease | 28.5 ± 6.2 |
Autoimmune diseases | |
Search for autoimmune disease | 39.2 ± 5.6 |
ANA | 69.9 ± 4.9 |
Heart/lung diseases | |
Pulmonary disease | 48.4 ± 7.0 |
Heart disease | 53.6 ± 6.9 |
Pregnancy | 64.2 ± 7.2 |
Domain C: Management under TNF inhibitors | |
First visit 12 to 16 weeks after TNF-inhibitor initiation ± 1 wk | 48.7 ± 5.6 |
BASDAI assessment | 33.3 ± 5.3 |
NSAID intake | 49.1 ± 5.3 |
Safety assessment | 80.0 ± 5.3 |
↵* ASAS or modified New York classification criteria. TNF: tumor necrosis factor; SpA: spondyloarthritis; ASAS: Assessment of Spondyloarthritis international Society; TB: tuberculosis; HIV: human immunodeficiency virus; SPEP: serum protein electrophoresis; MS: multiple sclerosis; ANA: anti-nuclear antibodies; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; NSAID: nonsteroidal antiinflammatory drug.